Drug combo helps High-Risk kidney cancer patients avoid full kidney removal
NCT ID NCT06138496
First seen Jan 05, 2026 · Last updated May 23, 2026 · Updated 22 times
Summary
This study tested a combination of two drugs (cadonilimab and lenvatinib) given before surgery to 39 people with kidney cancer that was difficult to operate on. The goal was to shrink the tumor enough so that only the cancerous part of the kidney could be removed, sparing the rest of the kidney. The approach aims to make surgery safer and preserve kidney function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Other (Non U.s.), 0755, China
Conditions
Explore the condition pages connected to this study.